Sabby Management’s Viking Therapeutics VKTX Stock Holding History

Sabby Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-72,500	Closed	-$607K	–	126
2018 Q4	$555K	Sell	72,500 -90,963	-56%	-$1.09M	0.12%	48
2018 Q3	$2.85M	Buy	+163,463	New	+$1.95M	0.36%	37
2017 Q3	–	Sell	-486,491	Closed	-$525K	–	208
2017 Q2	$525K	Buy	+486,491	New	+$619K	0.03%	135

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Sabby Management's VKTX Position: Q1 2019 in Review

Sabby Management sold out of Viking Therapeutics (VKTX) in Q1 2019, closing a stake of 72,500 shares — an estimated $607K sold.

Sabby Management first reported a position in VKTX in Q2 2017 and held it in 3 quarters. The position peaked at $2.85M in Q3 2018. 164 funds tracked by Wall St. Rank hold VKTX as of Q1 2019.

Sabby Management reported no remaining Viking Therapeutics position as of Q1 2019 after selling out during the quarter.
Sabby Management sold 72,500 Viking Therapeutics shares in Q1 2019, an estimated $607K.
Sabby Management first reported a position in Viking Therapeutics in Q2 2017 and held it in 3 quarters.
Sabby Management's Viking Therapeutics position peaked at $2.85M in Q3 2018.
164 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.